Wits contributes to global trial on best antibiotics for bloodstream infection
Researchers from Wits University participated in a global clinical trial that identified more effective antibiotic treatments for golden staph bloodstream infections. The study suggests that flucloxacillin should no longer be the default treatment, favoring cefazolin and benzylpenicillin instead.
Why it matters
This breakthrough could significantly improve survival rates for a life-threatening condition that causes over a million deaths annually worldwide.
Researchers from Wits University have contributed to a landmark global antibiotics trial for life-threatening golden staph bloodstream infections, with the findings being published this month in both The New England Journal of Medicine as well as The Lancet .
The report is a straightforward summary of medical trial results and their clinical implications.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in